Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lehman Brothers Global Healthcare Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...

You may also be interested in...



Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains

Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31

Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains

Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31

AdvaMed 2004 Annual Meeting In Brief

Code of ethics roll-out: To generate adoption of its ethics code beyond member companies, AdvaMed has mailed a related brochure to 130,000 healthcare professionals, as well as a letter from President Pam Bailey to 3,000 healthcare professional societies and 2,000 hospitals, Exec VP-Strategic Planning & Implementation Blair Childs reports. Bailey also is calling 30 "major physician organizations" to discuss collaborative opportunities, Childs notes. The voluntary code, announced at last year's annual meeting, became effective Jan. 1 (1"The Gray Sheet" March 24, 2003, p. 6)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel